B7-H1
E1423945
UNEXPLORED
B7-H1, also known as PD-L1, is an immune checkpoint protein expressed on various cells that modulates T-cell activity and is targeted by certain cancer immunotherapies.
All labels observed (1)
| Label | Occurrences |
|---|---|
| B7-H1 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T20301132 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: B7-H1 Context triple: [Imfinzi, hasMolecularTarget, B7-H1]
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
programmed cell death protein 1
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
-
C.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
D.
CD22
CD22 is a B-cell–specific surface glycoprotein that functions as an inhibitory co-receptor modulating B cell receptor signaling and immune responses.
-
E.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: B7-H1 Target entity description: B7-H1, also known as PD-L1, is an immune checkpoint protein expressed on various cells that modulates T-cell activity and is targeted by certain cancer immunotherapies.
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
programmed cell death protein 1
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor on T cells that downregulates immune responses and promotes self-tolerance, making it a key target in cancer immunotherapy.
-
C.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
D.
CD22
CD22 is a B-cell–specific surface glycoprotein that functions as an inhibitory co-receptor modulating B cell receptor signaling and immune responses.
-
E.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.